Type 1 Diabetes
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
The study will investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels in participants with Type 1 Diabetes on insulin injection therapy. Side effects and tolerability will be documented.
The results of this study are not yet available.
Your participation could last up to 14 weeks and include 13 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participants must have Type 1 Diabetes Mellitus (T1DM) and be on a stable multiple daily injection regimen with a short-acting and long-acting insulin
Participants must have a body mass index (BMI) of 18.5 to 33.0
Participants must have no episodes of severe hypoglycemia in the past 6 months
Participants must not be treated with a continuous subcutaneous insulin infusion (insulin pump)
Participants must not have had blood loss of more than 500 milliliters (mL) within the last month
Participants must not have previously participated or withdrawn from this study